2020. Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s84. DOI:https://doi.org/10.25251/skin.4.supp.84.